$140 Million is the total value of DAFNA Capital Management LLC's 75 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LOXO | Buy | LOXO ONCOLOGY INC | $24,347,000 | +92.4% | 303,621 | +1.0% | 17.37% | +62.3% |
| IMMU | Buy | IMMUNOMEDICS INC | $5,631,000 | +244.6% | 637,700 | +152.5% | 4.02% | +190.7% |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $5,611,000 | +164.5% | 106,770 | +128.3% | 4.00% | +123.2% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $3,287,000 | -27.7% | 591,128 | +9.2% | 2.35% | -39.0% |
| GLPG | Buy | GALAPAGOS NVspon adr | $2,954,000 | -3.1% | 38,609 | +9.2% | 2.11% | -18.2% |
| NERV | Buy | MINERVA NEUROSCIENCES INC | $2,445,000 | +197.8% | 276,317 | +172.7% | 1.74% | +151.4% |
| RDUS | Buy | RADIUS HEALTH INC | $2,411,000 | +27.8% | 53,309 | +9.2% | 1.72% | +7.8% |
| DERM | Buy | DERMIRA INC | $2,200,000 | +130.4% | 75,500 | +169.6% | 1.57% | +94.3% |
| AGTC | Buy | APPLIED GENETIC TECHNOL CORP | $2,147,000 | -24.3% | 421,000 | +2.4% | 1.53% | -36.1% |
| SGMO | New | SANGAMO THERAPEUTICS INC | $1,980,000 | – | 225,000 | +100.0% | 1.41% | – |
| AKBA | Buy | AKEBIA THERAPEUTICS INC | $1,951,000 | +201.1% | 135,738 | +92.7% | 1.39% | +154.0% |
| ARDX | Buy | ARDELYX INC | $1,904,000 | -32.1% | 373,409 | +68.4% | 1.36% | -42.7% |
| VYGR | Buy | VOYAGER THERAPEUTICS INC | $1,835,000 | +94.4% | 204,808 | +187.2% | 1.31% | +64.0% |
| New | DERMIRA INCnote 3.000% 5/1 | $1,665,000 | – | 1,500,000 | +100.0% | 1.19% | – | |
| FOMX | Buy | FOAMIX PHARMACEUTICALS LTD | $1,650,000 | +2.4% | 355,667 | +9.2% | 1.18% | -13.6% |
| ADXS | Buy | ADVAXIS INC | $1,603,000 | +14.1% | 247,000 | +43.6% | 1.14% | -3.7% |
| NEOS | Buy | NEOS THERAPEUTICS INC | $1,532,000 | +123.3% | 209,873 | +120.3% | 1.09% | +88.4% |
| ACHN | Buy | ACHILLION PHARMACEUTICALS | $1,223,000 | +47.9% | 266,500 | +35.6% | 0.87% | +24.9% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $1,190,000 | -12.4% | 377,695 | +11.2% | 0.85% | -26.1% |
| Buy | NEURODERM LTD | $1,134,000 | +14.1% | 37,938 | +1.3% | 0.81% | -3.8% | |
| ASND | Buy | ASCENDIS PHARMA A Ssponsored adr | $922,000 | +80.8% | 33,214 | +82.4% | 0.66% | +52.7% |
| SCYX | Buy | SCYNEXIS INC | $907,000 | -13.9% | 506,900 | +32.7% | 0.65% | -27.4% |
| ARGX | New | ARGENX SEsponsored adr | $848,000 | – | 40,000 | +100.0% | 0.60% | – |
| MASI | Buy | MASIMO CORPORATION | $388,000 | +19.0% | 4,250 | +21.4% | 0.28% | +0.4% |
| NTUS | New | NATUS MDICAL INC DEL | $295,000 | – | 7,900 | +100.0% | 0.21% | – |
| CNAT | New | CONATUS PHARMACEUTICALS INC | $288,000 | – | 50,000 | +100.0% | 0.21% | – |
| ARNA | New | ARENA PHARMACEUTICALS INC | $262,000 | – | 15,550 | +100.0% | 0.19% | – |
| New | DEXCOM INCdbcv 0.750% 5/1 | $254,000 | – | 250,000 | +100.0% | 0.18% | – | |
| SBPH | New | SPRING BANK PHARMACEUTICALS | $217,000 | – | 1,600 | +100.0% | 0.16% | – |
| EDGE | New | EDGE THERAPEUTICS INC | $199,000 | – | 19,400 | +100.0% | 0.14% | – |
| ARRY | New | ARRAY BIOPHARMA INC | $167,000 | – | 20,000 | +100.0% | 0.12% | – |
| ANAB | Buy | ANAPTYSBIO INC | $132,000 | +5.6% | 5,500 | +22.2% | 0.09% | -11.3% |
| New | TRILLIUM THERAPEUTICS INC | $88,000 | – | 20,000 | +100.0% | 0.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.